Skip to main content
. 2020 Jan 3;21(1):327. doi: 10.3390/ijms21010327

Figure 4.

Figure 4

DDI2-deficient MDA-MB-231 cells exhibit greater sensitivity to carfilzomib in a pulse treatment scheme. (A) MDA-MB-231 control (wild-type) and DDI2−/− cells were pulsed with increasing doses of CFZ (25–400 nM) for 1 h. CFZ was washed out with PBS and cells were given 24 h to recover in normal media, then analyzed by a luminescent cell viability assay. Viability percentage was determined via comparison to viability of untreated cells (100%). Error bars denote standard deviation (n = 3). (B) MDA-MB-231 control (wild-type) and DDI2−/− cells were pulsed with 400 nM CFZ for 1 h. The CFZ was washed out with PBS and cells were given 24 h to recover in normal media, then analyzed by western blot using the antibodies indicated. β-Actin was used as a loading control. Blots shown are representative of three independent experiments. Significance (p value < 0.05) is denoted by asterisk.